Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-07-08

EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

EU authorization of Altuvoct (efanesoctocog alfa) for Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Altuvoct (efanesoctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 03/07/2026. Orphan medicine